InSilico Medicine Cayman TopCo (HKG:3696)
Hong Kong
· Delayed Price · Currency is HKD 61.95
-0.90 (-1.43%)
At close: Feb 27, 2026
InSilico Medicine Cayman TopCo Company Description
InSilico Medicine Cayman TopCo operates as an artificial intelligence (AI)-based biotech company that helps to develop and manufacture novel drugs in Hong Kong, the United States, the United Kingdom, Mainland China, and internationally.
The company develops solutions to discover and develop drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
It also offers Pharma.AI platform, a commercially end-to-end generative Al software and automation platform which is designed to enhance the quality and productivity of pharmaceutical research.
The company was founded in 2014 and is based in New Territories, Hong Kong.
InSilico Medicine Cayman TopCo
| Country | Cayman Islands |
| Founded | 2014 |
| Industry | Software - Infrastructure |
| Sector | Technology |
Contact Details
Address: Building 8W, Phase 2 Hong Kong Hong Kong | |
| Phone | 852 1626 5937 957 |
| Website | insilico.com |
Stock Details
| Ticker Symbol | 3696 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Dr. Feng Ren Ph.D. | CO-Chief Executive Officer, Chief Scientific Officer and Executive Director |
| Dr. Alexander Zhavoronkov Ph.D. | Founder, Chief Executive Officer, Chief Business Officer and Chairman of the Board |
| Aleksandr Aliper Ph.D. | President |
| Peng Dai | Vice President and Head of Finance |
| Dr. Xiao Ding | Head of Chemistry |
| Dr. Man Zhang | Head of Biology |
| Leung Kwan Wai | Company Secretary |